IRCT20230903059342N4 IRCT 2025-11-11 Bagheiat-allah University of Medical Sciences Evaluation of Neuroblastoma cancer treatment by optimized measles vaccine The first phase and second of the trial investigating the safety and efficacy of Intratumorally optimized measles vaccine in patients with Neuroblastoma cancer 2025-11-22 anticipated 10 Recruiting https://irct.ir/trial/87327 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The randomization method is going to be done by the method of random blocks of 6 random strings with a length of 15 coincidences with a ratio of 2 to 1. This string is created by one of the online randomization software. In order to hide the randomization, the method of closed envelopes will be used. 1-2 Neuroblastoma Cancer. Intervention 1: Intervention group: includes patients who, in addition to standard treatment, receive the optimized measles vaccine intraperitoneally in 2 doses 4 weeks apart. At the same time as being treated with the optimized measles vaccine, the patient receives standard treatments including chemotherapy and immunotherapy. In fact, the intervention is in the form of adjuvant therapy. Intervention 2: Control group: They receive only standard treatment including chemotherapy and immunotherapy and no intervention is done in their standard treatment. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information